Answer
The licensed treatment combines the tezacaftor–ivacaftor tablet with a separate ivacaftor tablet to maintain CFTR potentiation as directed by the specialist team.
Sources for this answer
- Symkevi 100 mg/150 mg tablets PLGB 22352/0003 — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.